OpenAI unveils GPT-Rosalind for drug discovery research

OpenAI announced GPT-Rosalind, an AI model for life‑sciences research, and will provide an early research preview to business customers including Amgen, Moderna and the Allen Institute.

OpenAI has introduced GPT-Rosalind, an early artificial intelligence model intended to support life sciences research. The company said the model is designed to help glean insights from large datasets and to translate scientific studies into health‑care applications. OpenAI announced GPT-Rosalind will be available initially as a research preview to some of its business customers. Initial users named by the company include Amgen, Moderna and the Allen Institute. Key details: - GPT-Rosalind is presented as a tool for biology work that is increasingly reliant on computers, such as analyzing large volumes of data and assisting in translating research into applications. - The model will be offered first as a research preview to select business customers, with Amgen, Moderna and the Allen Institute among the initial users. - OpenAI leaders said they do not yet expect AI alone to produce new treatments but see the model as a way to help researchers move faster through complex and time‑intensive parts of the scientific process. - The article mentions shares of several companies involved in drug discovery fell after the announcement, naming IQVIA, Charles River Laboratories, Recursion Pharmaceuticals and Schrodinger. - The report notes other AI developers, including Anthropic and Google’s DeepMind, are also focusing on scientific and health‑care applications, and it references AlphaFold’s role and the 2024 Nobel Prize in chemistry. - OpenAI said the system includes "high‑precision flags" to surface indicators or thresholds related to biological risks and to evaluate whether an organization can safely use the model. Summary: OpenAI will provide GPT-Rosalind as a research preview to select business customers and expects the model to help speed data‑intensive biology work; the article mentions a market reaction with some drug‑discovery company shares falling after the announcement. Undetermined at this time.